

Thursday 29 September 2022

08:30 - 10:00	<p>Plenary Session 4 Main Auditorium</p> <p>Co-chair: Kirsty Short, University of Queensland, Australia Co-chair: Sheena Sullivan, Doherty Institute, Australia</p>		
08:30 - 09:00	<p>Advances in our Understanding of SARS-CoV-2 Yoshihiro Kawaoka, University of Wisconsin-Madison, USA</p>		
09:00 - 09:30	<p>Can Human Challenge Models Accelerate Respiratory Virus Vaccine Development? Kathleen Neuzil, University of Maryland, USA</p>		
09:30 - 10:00	<p>The Perils of Predicting Epidemics: How Untangling Transmission Drivers Can Improve Forecasting Adam Kucharski, London School of Hygiene & Tropical Medicine, UK</p>		
10:00 - 10:30	<p>Tea break Hall 1</p>		
	<p>Virology & Pathogenesis HALL 1A</p>	<p>Clinical Sciences & Vaccinology THE STUDIO</p>	<p>Public Health & Policy MAIN AUDITORIUM</p>
10:30 - 12:00	<p>Zoonotic Influenza</p>	<p>Influenza & COVID-19 - Human Challenge Models</p>	<p>Vaccine Effectiveness for Influenza</p>
	<p>Co-chair: Kirsty Short, University of Queensland, Australia Co-chair: Rafael Medina Silva, Pontificia Universidad Católica de Chile, Chile</p>	<p>Co-chair: Brooke Bozick, National Institutes of Health, USA Co-chair: Jordan Clark, The Icahn School of Medicine at Mount Sinai, USA</p>	<p>Co-chair: Takeshi Arashiro, National Institute of Infectious Diseases, Japan Co-chair: Nancy Leung, University of Hong Kong, Hong Kong</p>
10:35 - 11:00	<p>Characterising influenza A virus evolution from a One Health standpoint: towards protecting human and animal health Nicola Lewis Francis Crick Institute, UK</p>	<p>Determinants of susceptibility to infection and disease in SARS-CoV-2 and influenza human infection challenge Christopher Chiu Imperial College London, UK</p>	<p>Immunogenicity of repeated influenza vaccination in older adults Nancy Leung University of Hong Kong, Hong Kong</p>
11:00 - 11:12	<p>Influenza A (H11N2) detection in fecal samples from Adelle (Pygoscelis adeliae) and chinstrap (Pygoscelis antarcticus) penguins, Penguin Island, Antarctic [AOXI0520] Maria Ogrzewalska, Oswaldo Cruz Foundation, Brazil</p>	<p>Local and systemic mediators associated with symptomatic and asymptomatic infection after human influenza A(H3N2) challenge [AOXI0499] Loukas Papagryris, Imperial College London, UK</p>	<p>Vaccine effectiveness against influenza A and A(H3N2): Results from the 2021-22 season European I-MOVE primary care multicentre study [AOXI0336] Esther Kissling, EpiConcept, France</p>
11:12 - 11:24	<p>Preparing for the next pandemic: Impact of pigs challenged with pre-pandemic, swine-adapted and human-adapted influenza A H1N1pdm09 viruses [AOXI0128] Charlotte Kristensen, University of Copenhagen, Denmark</p>	<p>Influenza, COVID-19, RSV and HRV: translating efficacy testing of vaccine and drugs from human challenge models to the field [AOXI0658] Alex Mann, hVIVO, UK</p>	<p>Absolute and Relative Effectiveness of Cell Culture-Based Inactivated Influenza Vaccine against Medically-Attended, Laboratory-Confirmed Influenza in Northcentral Wisconsin, US, 2019-20 [AOXI0066] Kayla Hanson, Marshfield Clinic Research Institute, USA</p>
11:24 - 11:36	<p>Mapping the molecular basis of antigenic evolution of H5 highly pathogenic avian influenza viruses to support the design of broadly reactive vaccines [AOXI0623] Mathilde Richard, Erasmus MC, Netherlands</p>	<p>Efficacy and safety of SAB-176, a novel anti-Type A and B influenza immunotherapeutic: a Phase 2a, randomized, double blind trial in H1N1 challenged adults [AOXI0452] Thomas Luke, SAB Biotherapeutics, Inc, United States</p>	<p>Effectiveness of Influenza Vaccination During Pregnancy On Laboratory-Confirmed Seasonal Influenza Among Infants Under 6 Months of Age in Ontario, Canada [AOXI0236] Deshayne Fell, Children's Hospital of Eastern Ontario, Canada</p>
11:36 - 11:48	<p>Cross-species spill-over potential of the H9N2-like bat influenza virus [AOXI0175] Ghazi Kayali, Human Link DMCC, United Arab Emirates</p>	<p>How human challenge studies reveal vaccine efficacy and mode of action [AOXI0161] Fuminari Miura, National Institute for Public Health and the Environment, Netherlands</p>	<p>Using serological data to identify cryptic influenza infections and effect on vaccine responses [AOXI0282] David Hodgson, London School of Hygiene and Tropical Medicine, UK</p>
11:48 - 12:00	<p>Rapid surge of the H1pdm11av reassortant in Danish swine and its zoonotic potential [AOXI0099] Pia Ryt-Hansen, University of Copenhagen, Denmark</p>	<p>The key facets that drive success or failure of influenza challenge studies in vaccine and antiviral testing: learning from past challenge studies [AOXI659] Nicolas Noulin, hVIVO, UK</p>	<p>Influenza virus dynamics in uncomplicated infection: impact of age and vaccination [AOXI0302] Melissa Rolfes, Centers for Disease Control and Prevention, USA</p>
12:00 - 13:00	<p>Lunch Hall 1A Hall 1 Exhibition Closes at 13:00</p>		
12:00 - 12:40 HALL 1A	<p>Flu, COVID and RSV: how to vaccinate? Chair: Colin Russell (ESWI Vice-Chair) University of Amsterdam UMC, the Netherlands</p> <p>30 Years of ESWI: an overview Ab Osterhaus, ESWI Chair, TIHO</p> <p>The Prospect of RSV Vaccination Peter Openshaw, ESWI Board Member, Imperial College</p> <p>COVID-19: How to Vaccinate Adolfo Garcia-Sastre, Icahn School of Medicine at Mount Sinai</p> <p>Influenza Vaccines 2022 and the Future Kanta Subbarao, WHO Collaborating Centre for Reference and Research on Influenza, Melbourne</p>		
12:40 - 13:00 HALL 1A	<p>WHO/GISAID Session - Surveillance: Influenza, COVID-19 and RSV</p> <p>Wenqing Zhang WHO, Switzerland</p> <p>Sebastian Maurer-Stroh Bioinformatics Institute (BII), A*Star, Singapore</p>		

13:00 - 14:30	SARS-CoV-2: Novel Treatment and Prevention Strategies	Surveillance for Influenza Including Joint Surveillance and Impact of COVID-19 on other Respiratory Virus Diseases	Vaccine Effectiveness for COVID-19 and Implications for Influenza
	HALL 1A	THE STUDIO	MAIN AUDITORIUM
	Co-chair: Paul Thomas, St. Jude Children's Research Hospital, USA Co-chair: Michael Schotsaert, Ichan School of Medicine at Mount Sinai, USA	Co-chair: John McCauley, Francis Crick Institute, UK Co-chair: Sibongile Walaza, National Institute for Communicable Diseases, South Africa	Co-chair: Sheena Sullivan, Doherty Institute, Australia Co-chair: Joe Lewnard, University of California - Berkeley, USA
13:05 - 13:30	Understanding virus-host interactions to control SARS-CoV-2 Laura Martin-Sancho The Scripps Research Institute, USA	Multipathogen surveillance to guide public health action during a pandemic Sibongile Walaza National Institute for Communicable Diseases, South Africa	Observational studies of COVID-19 vaccine effectiveness: challenges and opportunities Joe Lewnard University of California, Berkeley, USA
13:30 - 13:42	CYP19A1 mediated sex hormone metabolism promotes severe SARS-CoV-2 disease outcome in males [AOX10241] Sebastian Beck, Leibniz Institute of Virology, Germany	Rapid Oral Session 13:30-13:36 The echoes of COVID-19 on avian influenza prevalence and risk: stories from Cambodia [AOX10548] Erik Karlsson, Institut Pasteur du Cambodge, Cambodia 13:36-13:42 Impact of COVID-19 on influenza surveillance during 2020 in Ghana [AOX10177] Yaw Awuku-Larbi, Noguchi Memorial Institute for Medical Research, Ghana	Leveraging influenza vaccine effective networks for COVID-19 vaccine effectiveness studies [AOX10239] Brendan Flannery, Centers for Disease Control and Prevention, USA
13:42 - 13:54	OVX033, T-cell based vaccine targeting the Nucleocapsid provides broad-spectrum protection against SARS-CoV-2 VoC in hamster challenge model [AOX10230] Alexandre Le Vert, Osivax, France	13:42-13:48 Utilization of influenza surveillance platform to monitor SARS-CoV-2: findings from hospital-based influenza sentinel surveillance during first two years of COVID-19 in Bangladesh [AOX10183] Md Ariful Islam, International Centre for Diarrhoeal Disease, Bangladesh 13:48-13:54 Surveillance of Influenza and SARS CoV2 and Impact of COVID-19 on Other Respiratory Viral diseases in Pune western part of India [AOX10254] Varsha Potdar, National Institute of Virology Pune, India	AFRO-MoVE: African network to monitor vaccine effectiveness for COVID-19 and other respiratory pathogens [AOX10407] Celine Gurry, EpiConcept, France
13:54 - 14:06	Development and application of a next-generation single-dose mucosal COVID-19 vaccine [AOX10461] Michael D'Agostino, McMaster University, Canada	13:54-14:00 Results from a test-and-treat study for influenza and impact of the SARS-CoV-2 pandemic on influenza prevalence among residents of homeless shelters in King County, WA: a stepped-wedge cluster-randomized trial [AOX10179] Julia Rogers, University of Washington, USA 14:00-14:06 Atypical seasonality of Influenza A(H3N2) in Brazil 2021/2022 and mismatch with the vaccine strain [AOX10633] Paola Cristina Resende, FIOCRUZ, Brazil	Monitoring COVID-19 vaccine effectiveness against symptomatic infection with variants of concern through home-based testing in King County, Washington [AOX10208] Chelsea Hansen, Fogarty International Center, USA
14:06 - 14:18	CLAROMERS: Synthetic oligomer mimics of antimicrobial peptides for treatment and prevention of SARS-CoV-2 and other respiratory viruses [AOX0472] Kent Kirshenbaum, New York University / Maxwell Biosciences, USA	14:06-14:12 Late influenza A(H3N2) season after relaxation of COVID-19 restrictions driven by the 7-14 years old [AOX10227] Hanne-Dorthe Emborg, Statens Serum Institut, Denmark 14:12-14:18 Increased severity of influenza-related hospitalizations in resource-limited settings: Results from the Global Influenza Hospital Surveillance Network (GIHSN) [AOX10190] Lily E. Cohen, The Taskforce for Global Health, USA	Homologous and heterologous boosting with third-dose BNT162b2 and CoronaVac: a randomized trial (Cobovax study) [AOX10516] Nancy Hiu Lan Leung, University of Hong Kong, Hong Kong
14:18 - 14:30	Modulation of the renin-angiotensin system to reduce immunopathology in SARS-CoV-2 and influenza A infection [AOX10093] Melanie Wu, University of Queensland, Australia	14:18-14:24 Profiling the avian influenza antibody repertoires of wild migratory birds using influenza antigen microarrays [AOX10533] Lilach M. Friedman, Ben Gurion University of the Negev, Israel	Symptom severity and long-COVID in vaccinated and unvaccinated individuals [AOX10635] Theresa Kowalski-Dobson, University of Michigan, USA
14:30 - 15:00	Tea break HALL 2		
15:00 - 15:40	Closing Keynote Address MAIN AUDITORIUM Chair: John Wood, Deputy Chair isirv		
15:05 - 15:40	Influenza Research in the Post-COVID era Wendy Barclay, Imperial College London, UK		
15:40 - 16:00	Award Presentations & Closing Remarks		